Checkpoint Therapeutics (CKPT) 10-K2019 FY Annual report

Filed: 11 Mar 20, 5:14pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: alluded, attrition, Australian, Barcelona, black, box, cap, ceiling, Celgene, center, chain, Charter, Chinese, civilian, Colombia, Commerce, concept, cosibelimab, CRO, curb, draft, ESMO, Excellence, explore, explored, fashion, filling, freestanding, freeze, herewith, immunotherapy, instituteinter, Japanese, Judiciary, Jumpstart, justify, Korean, landscape, lifted, marked, Mivebresib, molibresib, mutually, Myanmar, neutrality, Notably, OMB, omitted, outbreak, overhaul, poster, push, relatedly, replicated, routine, rulemaking, rural, Russian, Society, Spain, theInternational, thereunder, unclear, unreserved, untitled, withdrawn, workforce

Removed: acted, clarify, classification, closed, cohort, conceivable, conflicting, consolidation, contraindication, disputed, DSMB, EMA, finally, Forma, GLP, goodwill, heavily, library, preclusive, repair, retrospective, stable, unproven, validated, varied

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CKPT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

Checkpoint Therapeutics, Inc.

New York, New York

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-221493) and Form S-8 (No. 333-216856 and 333-221488) of Checkpoint Therapeutics, Inc. of our report dated March 11, 2020, relating to the financial statements which appears in this Form 10-K.

/s/ BDO USA, LLP

New York, New York

March 11, 2020

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.